Founded in 2007, Dicerna Pharmaceuticals has raised approximately $110 million in venture capital funding. Dicerna’s investors include:
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. The company invests across all stages of company development, including early- and late-stage venture financing, growth equity and public companies. Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Abingworth has a specialist team of over 20 professionals with a broad range of skills, including scientific and business expertise, as well as investment banking, recruitment and legal knowledge. Abingworth has funds under management of more than $1.25 billion and offices in London, Menlo Park (Calif.) and Boston.
Brookside Capital is the public equity affiliate of Bain Capital. The principal investment objective of the Fund is to achieve capital appreciation through investing primarily in publicly traded equity securities globally. Brookside employs an experienced team of industry oriented investment professionals to achieve its investment objective. The Brookside team evaluates investments based on in-depth strategic and financial analysis, emphasizing industry fundamentals, competitive position and management capability.
Deerfield is a leading investment management firm, committed to advancing healthcare through investment, information and philanthropy. Deerfield launched in 1994 with $17 million in equity, and today manage funds in excess of $3.5 billion. Deerfield works with companies from across the breadth of the healthcare spectrum, from early stage drug research businesses to mature healthcare service and medical device companies.
Domain Associates, LLC was formed in 1985 to permit its founding partners to continue to serve as the U.S. Advisor to Biotechnology Investments Ltd. (BIL), the first life science focused venture investment fund. BIL counted among its initial investments several of today’s dominant life science companies, including Amgen, Applied Biosystems and Genzyme. Over the past 24 years, Domain has raised eight Domain Partners funds with assets exceeding $2.7 billion. These funds have created and invested in more than 200 life science companies.
Omega Funds is a leading international healthcare focused investment firm. Omega was established in 2004, and today manages six funds with investments across Europe, North America and the Far East. Omega invests in both public and private companies, completing investments across all healthcare sectors, including biotech, medtech, diagnostics, services and healthcare IT since inception.
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1 billion of committed capital under management, OBP has invested in more than 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
RA Capital Advisors is a private investment bank. The company’s differentiated advisory model is focused on building long-term relationships that create value for its clients. Artful positioning of companies and deal structuring are core competencies that have led to the execution of transactions by the firm and its principals totaling more than $60 billion.
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Skyline’s areas of expertise include small molecule and protein therapeutics, medical devices, diagnostics, and technologies that facilitate drug discovery and life science research.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately $600 million in more than 130 companies.